BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
11/19/2014 10:25:00 AM | Browse: 1398 | Download: 1032
Publication Name World Journal of Gastrointestinal Pathophysiology
Manuscript ID 9447
Country/Territory Greece
Received
2014-02-12 23:57
Peer-Review Started
2014-02-13 09:58
To Make the First Decision
2014-02-27 09:34
Return for Revision
2014-03-11 21:25
Revised
2014-04-15 00:22
Second Decision
2014-07-17 14:18
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief
2014-07-17 14:35
Articles in Press
2014-07-17 14:51
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript
2014-10-29 17:22
Publish the Manuscript Online
2014-11-19 10:25
ISSN 2150-5330 (online)
Open Access
Copyright
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Gastroenterology & Hepatology
Manuscript Type Topic Highlights
Article Title Treatment of Helicobacter pylori infection: Past, present and future
Manuscript Source Invited Manuscript
All Author List Vasilios Papastergiou, Sotirios D Georgopoulos and Stylianos Karatapanis
Funding Agency and Grant Number
Corresponding Author Stylianos Karatapanis, MD, PhD, Department of Internal Medicine, General Hospital of Rhodes, 10 Kalopetras Str, 85100 Rhodes, Greece. stylkar@otenet.gr
Key Words Helicobacter pylori; Antibiotic resistance; Bismuth-quadruple; Concomitant; Sequential; Probiotics
Core Tip Worldwide increase in prevalence of macrolide resistance has accounted for the failure of standard therapies for the treatment of Helicobacter pylori (H. pylori) infection. Bismuth quadruple, concomitant, sequential and hybrid therapies are now recommended as first-line empirical treatments providing improved efficacy in high clarithromycin resistance settings. As quinolone resistance is rapidly increasing, levofloxacin should be preferentially used in second-line/rescue therapies. There is increasing evidence that adjunct probiotic supplementation improves the therapeutic outcome and tolerability. Genotypic characterization of H. pylori susceptibility to therapy may allow for a tailored therapeutic approach in the future.
Publish Date 2014-11-19 10:25
Citation Papastergiou V, Georgopoulos SD, Karatapanis S. Treatment of Helicobacter pylori infection: Past, present and future. World J Gastrointest Pathophysiol 2014; 5(4): 392-399
URL http://www.wjgnet.com/2150-5330/full/v5/i4/392.htm
DOI http://dx.doi.org/10.4291/wjgp.v5.i4.392
Full Article (PDF) WJGP-5-392.pdf
Full Article (Word) WJGP-5-392.doc
Manuscript File 9447-Review.docx
Answering Reviewers 9447-Answering reviewers.pdf
Copyright License Agreement 9447-Copyright assignment.pdf
Peer-review Report 9447-Peer review(s).pdf
Scientific Misconduct Check 9447-CrossCheck.jpg
Scientific Editor Work List 9447-Scientific editor work list.pdf